렌티바이러스 벡터 CDMO(의약품 개발 제조 수탁 기관) : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2024-2029년)

The Lentiviral Vector Contract Development And Manufacturing Organizations Market size is estimated at USD 161.64 million in 2024, and is expected to reach USD 231.89 million by 2029, growing at a CAGR of 6.20% during the forecast period (2024-2029).

Cell and gene therapy's growing emphasis and development are expected to contribute to the lentiviral vector CDMO market growth. Cell and gene therapies have demonstrated remarkable success in treating previously untreatable or difficult-to-treat diseases, including certain types of cancer, genetic disorders, and autoimmune conditions. For instance, in September 2023, BioViros, a full-service CDMO specializing in lentiviral vectors for cell and gene therapy, announced the opening of its state-of-the-art laboratory for lentiviral vectors in New Zealand. Additionally, in January 2023, Vector BioMed has innovated a technological platform for designing and producing lentiviruses utilized in cell and gene therapy delivery.

Moreover, increasing fundraising activities by the market players to expand the CDMO services is likely to contribute to the market growth. For instance, in January 2023, iVexSol Inc., a CDMO, announced USD 23.8 million in Series A-3 funding. The new funding will be used to invest in iVexSol's Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory, and cGMP operations, and augmenting existing infrastructure to support the production of stable lentiviral vector (LVV) producer cell lines.

Similarly, in January 2023, Vector BioMed commenced operations as a CDMO, receiving financial backing from Viking Global Investors and Casdin Capital's seed round. These funds will facilitate the scaling of commercial operations, enabling prompt delivery of premium lentiviral vectors for preclinical research, clinical trials, and commercial use. Vector BioMed specializes in providing solutions that empower partners to advance their lentiviral vector-based treatments into clinical trials, thereby expediting their journey to commercialization.

The heightened focus on cell and gene therapy and the surge in investment in lentiviral vector-based therapeutics, coupled with market players' strategic initiatives, are projected to propel market growth.Nevertheless, the limitations in scalability and the challenges with downstream purification are anticipated to limit market expansion during the forecast period.

Lentiviral Vector Contract Development And Manufacturing Organizations Market Trends

Cancer is Expected to Hold a Major Share in the Studied Market Over The Forecast Period.

Lentiviral vectors are a type of modified virus commonly used in gene therapy for cancer treatment. CDMOs are responsible for the design, development, and optimization of lentiviral vectors tailored for specific cancer therapies. This involves engineering vectors to efficiently deliver therapeutic genes to target cancer cells.

The increasing prevalence of cancer is drive the demand for advanced and effective therapeutics, leading to new investments by companies and other stakeholders, like governments, for the identification, testing, and development of novel cancer therapeutics. For instance, according to the Canadian Cancer Statistics 2023 report, about 239.2 thousand new cancer cases were reported in 2023 in Canada, compared to 233.9 thousand in 2022. Thus, the growing burden of cancer is expected to create the demand for drug development and manufacturing services which is likely to contribute to segment growth.

The increasing research & development activities and collaboration with CDMO providers to effectively complete the drug development process using lentiviral vectors are expected to contribute to segment growth. For instance, in March 2023, Eutilex, a partner of GenScript ProBio, a CDMO announced that Ministry of Food and Drug Safety (MFDS) clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio provided integrated plasmid and lentiviral vector CMC service to Eutilex and helped with the CTD document writing for MFDS IND filing.

Hence, increasing research and development activities involving lentiviral vectors are expected to create demand for CDMO services over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

The North American region is expected to dominate the market over the forecast period due to increasing research advancements in gene therapy, rising research for the development of new vaccines using lentivirus, and the presence of major market players offering lentiviral vector contract development and manufacturing services in the region.

North America is a hub for cutting-edge research in gene therapy and region is home to numerous academic institutions, biotech companies, and research organizations that are actively engaged in developing innovative gene-based treatments. For instance, in September 2022, Charles River a CDMO reported that the lentiviral vector platform enables a cost-effective and reliable path to GMP in less than seven months. Lentivation integrates the three pillars of plasmid DNA, lentiviral vector production, and testing, to provide LVV-based gene therapy and gene-modified cell therapy . Hence, the adoption of these services is expected to increase due to the benefits offered by the services, thereby boosting market growth.

Companies in North America often engage in collaborations and partnerships with academic institutions, research organizations, and other industry players. These collaborations facilitate knowledge exchange, give access to cutting-edge technologies, and pooling of resources for research and development. For instance, in September 2023, Kyverna Therapeutics announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc, a quality and innovation-led viral vector CDMO, enabling the use of LentiVector with any Kyverna product.

Hence, growing interest in cell and gene therapy, substantial investment, and strategic collaborations and partnerships are expected to boost the market in the North American region over the forecast period.

Lentiviral Vector Contract Development And Manufacturing Organizations Industry Overview

The lentiviral vector contract development and manufacturing organization market is fragmented in nature with the presence of many market players. They are continuously engaged in research and development activities, along with collaborations, partnerships, and facility expansion. Some of the key players in the lentiviral vector CDMO market are Thermo Fischer Scientific, Inc., Oxford Biomedica, Charles River Laboratories International, Inc., GenScript ProBio, Catalent Inc..and among other

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definitions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Research And Growing Emphasis On Cell And Gene Therapies
  • 4.2.2 Increasing Agreements and Collaborations
• 4.3 Market Restraints
  • 4.3.1 Lack Of Scalability And Downstream Purification
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Suppliers
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Component
  • 5.1.1 Lentiviral Promoter
  • 5.1.2 Lentiviral Fusion Tags
  • 5.1.3 Lentivirus Packaging Systems
  • 5.1.4 Other Components
• 5.2 By Disease Indication
  • 5.2.1 Cancer
  • 5.2.2 Genetic Disorders
  • 5.2.3 Infectious Diseases
  • 5.2.4 Veterinary Disease
  • 5.2.5 Other Disease Indication
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Company
  • 5.3.2 Academic Research
  • 5.3.3 Other End Users
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 United Kingdom
    • 5.4.2.2 Germany
    • 5.4.2.3 France
    • 5.4.2.4 Spain
    • 5.4.2.5 Italy
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia Pacific
    • 5.4.3.1 India
    • 5.4.3.2 Japan
    • 5.4.3.3 China
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of the Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Thermo Fischer Scientific, Inc
  • 6.1.2 Oxford Biomedica
  • 6.1.3 Charles River Laboratories International, Inc.
  • 6.1.4 Creative Biogene
  • 6.1.5 GenScript ProBio
  • 6.1.6 Merck KGaA
  • 6.1.7 Catalent Inc.
  • 6.1.8 Ask Bio
  • 6.1.9 Lonza
  • 6.1.10 Curia Global, Inc.
  • 6.1.11 Wuxi Advanced Therapies
  • 6.1.12 SIRION Biotech GmbH
  • 6.1.13 Oxford Genetics Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS